In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

CMV associated tissue-invasive disease is associated with a considerable risk of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Recently, the terminase inhibitor letermovir (LMV) has been approved for prophylaxis of CMV infection in HSCT. We hereby report a...

Full description

Bibliographic Details
Main Authors: Jochen J Frietsch, Detlef Michel, Thomas Stamminger, Friederike Hunstig, Sebastian Birndt, Ulf Schnetzke, Sebastian Scholl, Andreas Hochhaus, Inken Hilgendorf
Format: Article
Language:English
Published: PAGEPress Publications 2019-01-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Cytomegalovirus
hematopoietic stem cell transplantation
reactivation
letermovir
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/3708

Internet

https://www.mjhid.org/index.php/mjhid/article/view/3708

Similar Items